We're proud to have contributed to this milestone announced by the World Health Organization - marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh.
Since the pledge, Gilead has continued its long history in supporting reducing deaths from VL and controlling other neglected tropical diseases such as cryptococcal meningitis in efforts to advance global health equity.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
Claudia Hardy says she’s found her life’s mission. As director of Community Health Access and Relations for the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, she brings cancer resources and preventive care to communities.
Gilead Sciences, Inc. (Nasdaq: GILD) was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA).
Shortly after Sandra joined Gilead, this company ambition touched close to home. She worked on an acquisition that ended up being the backbone of Gilead’s work to develop a cure for hepatitis C.
Over the years, Gilead has thoughtfully and boldly focused on communities with the greatest unmet needs, and women and girls – in particular, Black women and girls – are always at the top of the list.
This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.
When Stacey Ma was a little girl, her dream was to work with patients as a doctor. “As it turns out, I became an engineer who makes medicine to help patients,” says Stacey, who joined Gilead last summer to lead the Pharmaceutical Development and Manufacturing (PDM) team
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...